Method of normalisation of platelet activity of neonatal calves with iron deficiency anaemia

FIELD: veterinary medicine.

SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.

EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.

1 ex

 

The invention relates to biology and veterinary medicine, namely to Hematology.

The closest analogue of the proposed method to normalize platelet activity in newborn calves with iron-deficiency anemia is EN 2462240 "the Way of normalization of thrombin time in newborn calves with iron deficiency anemia". In the prototype, as well as in the claimed method, is applied feroglobin, but as a single injection at the rate of 15 mg of iron per 1 kg of body weight of the calf, which is somewhat difficult to use this method because of the need for individualization of dosage. In addition, restistance used in the prototype glicerina ensures the occurrence of the claimed effect 50.0% later than in the claimed method. This is probably due to the fact that in the prototype in conjunction with the preparation of iron used only one metabolically active drug, are not able to cause the degree of stimulation of metabolism, which enables the use of two drugs contained in the claimed method.

Never before, feroglobin, krezacin and gamavit in the proposed dosing regimen was not used in newborn calves with iron deficiency anemia order relief for 4 days available to them thrombocytopathy with normalization of platelet aggregation with ADP, collagen, thrombin, restonic the nom, hydrogen peroxide, epinephrine -, and combinations of inductors - ADP + adrenaline, adrenaline + collagen, adrenaline + collagen, as well as optimization of intravascular platelet activity, eliminating the risk of development of microthrombi in the vessels, normalizing trophic tissues, growth and development of animals.

The aim of the invention is a complete normalization of platelet activity in newborn calves with iron deficiency anemia.

The essence of the proposed method lies in the fact that for the correction of platelet activity in newborn calves with iron-deficiency anemia is assigned solution feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg, starting simultaneously with ferroaluminum and krezacin 4 days.

The method enables stable to normalize platelet activity in newborn calves with iron deficiency anemia after a short correction, translating it to the level typical for healthy calves for 4 days of treatment and providing subsequent long-term maintenance of platelet aggregation in the optimal mode of operation, thereby significantly reducing the risk of thrombotic Oslo the Affairs and promoting normal growth and development of calves.

Example 1. Newborn calf No. 75 with iron deficiency anemia, the 2nd day of life, weight 33 kg were examined in terms of the calf. The calf was taken and examined the blood with the evaluation of the aggregation activity of platelets with a number of inductors (ADP 33,7 with, collagen 27,9, thrombin 36,0 C, H2O238,1, adrenaline and 82.2 C ADP + adrenaline 26,4 with, ADP + collagen 23,5 with, adrenaline + collagen 21,9) and the state of intravascular platelet activity (discocyte 71%, disco echinocyte 15%, ferocity 7%, sphere-echinocyte 6%, bipolar form 1%). The results obtained indicated the presence of calf platelet disorders.

Calves assigned to the solution feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin. This allowed the next day after the termination of the correction completely arrest the thrombocytopathies, to normalize aggregation activity of platelets (ADP 43,4 with, collagen is 37.2 C, thrombin and 57.6 C, H2About252,3 with, adrenaline 102,4, ADP + adrenaline 36,6 C ADP + collagen 33,4 with, adrenaline + collagen 34,3) and intravascular platelet activity (discocyte 84%) disco echinocyte 8%, SFU is ocity 4%, sphere-echinocyte 3%, bipolar form 1%), eliminating the risk of the calf thrombotic manifestations.

Further observation of this calf did not reveal negative dynamics of platelet activity, indicating a lack of risk thrombocytopathy.

Example 2. Newborn calf No. 67 with iron deficiency anemia, the 1st day of life, weight 29 kg, were examined in terms of the calf. The calf was taken and examined the blood with the evaluation of the aggregation activity of platelets with a number of inductors (ADP 31,9 with, collagen 25,8, thrombin 40,2, H2O230,8 with, adrenaline 75,5, ADP + adrenaline 26,9, ADP + collagen 21,2, adrenaline + collagen 22,8) and the state of intravascular platelet activity (discocyte 65%, disco echinocyte 16%, ferocity 12%, sphere-echinocyte 6%, bipolar form 1%), which allowed him to diagnose the thrombocytopathies with a tendency to hyperaggregation.

Calves assigned to the solution feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin. This allowed the next day after the end of correction to fully normalize thrombocyte the th activity (ADP 45,7 with, collagen 40,2, thrombin 56,6 s, H2O252,3 with, adrenaline 103, with, ADP + adrenaline 34,2, ADP + collagen 34,0, adrenaline + collagen 29,2) and intravascular platelet activity (discocyte 82%, disco echinocyte 7%, ferocity 5%, sphere-echinocyte 4%, bipolar form 2%), eliminating the risk of thrombotic disorders.

Further observation of the calf showed consistently normal platelet activity, excluding him recurrence risk of thrombosis.

The claimed method is tested on 45 newborn calves with iron deficiency anemia, showing 100% of cases the efficiency of correction of iron deficiency anemia and platelet activity.

The method of normalization of platelet activity in newborn calves with iron deficiency anemia, characterized in that simultaneously apply feroglobin 150 mg (2 ml) intramuscularly, twice with an interval of 4 days, krezacin 5 mg/kg per day, turning it into the schema drink for 4 days, starting simultaneously with the first injection feroglobin, and gamavit intramuscularly once daily in the morning 0.05 ml/kg for 4 days, starting simultaneously with ferroaluminum and krezacin.



 

Same patents:

FIELD: metallurgy.

SUBSTANCE: invention relates to casein succinylate of iron (III) wherein iron content varies from 4.5 wt % to 7 wt %, water solubility exceeds 92% while phosphorus-to-nitrogen ratio exceeds 5 wt %.

EFFECT: additionally, invention relates to production of iron (III) and to pharmaceutical composition containing casein succinylate of iron (III).

17 cl, 4 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to benzoimidazole derivatives of formula (I), as well as to their enantiomers, diastereoisomers, racemates and pharmaceutically acceptable salts, where n equals from 2 to 4, each of R1 substituents is independently selected from H, halogen, -C1-4alkyl, -C1-4pergaloalkyl, trifluoro-C1-4alkoxy, -NO2, -CN, CO2H, -OC1-4alkyl, -SC1-4alkyl, -S(C1-4alkyl)-Rc, -S(O)2(C1-4alkyl)-Rc, -S(O)-C1-4alkyl, -SO2-C1-4alkyl, -S-Rc, -S(O)-Rc, -SO2-Rc, -SO2-NH-Rc, -O-Rc, -CH2-O-Rc, -C(O)NH-Rc, -NRaRb, benzyloxy, phenyl, optionally substituted with one-two Rd, cyanobiphenyl-4-ylmethylsulpfanyl, cyanobiphenyl-4-ylmethanesulphonyl, or -S-(CH2)2-morpholine and two adjacent groups R1 can bind with formation of an aromatic 5-6-membered ring, optionally substituted with one methyl group or two atoms of halogen, optionally containing one or two S or N; Ra and Rb each independently represents C1-4alkyl, -C(O)C1-4alkyl, -C(O)-Rc, -C(O)CH2-Re, C1-4alkyl-Re, -SO2-Rc, -SO2-C1-4alkyl, phenyl, benzyl; or Ra and Rb together with a nitrogen atom, which they are bound with, form a monocyclic 5-6- membered heterocycloalkyl ring, optionally containing one heteroatom, selected from O; Rc represents -C3-8cycloalkyl, phenyl, optionally substituted with one-two Rd, benzyl, optionally substituted with one-three Rd; morpholine; Rd independently represents halogen, -OH, -C1-4alkyl or -C1-4perhalogenalkyl, trifluorine C1-4alcoxy, -OC1-4alkyl, or -O-benzyl optionally substituted with halogen, Re represents -C6heterocycloalkyl, optionally containing one or two of O or N atoms, optionally substituted with a methyl group; R2 and R3 both represent H, -CF3 or C1-3alkyl; each of Z represents a C or N atom, on condition that simultaneously not more than two Z represent N. The invention also relates to particular compounds, a pharmaceutical composition, based on formula (I) compound or a particular said compound, a method of treating diseases, mediated by propyl hydroxylase activity.

EFFECT: novel derivatives of benzimidazole, possessing an inhibiting activity with respect to PHD are obtained.

11 cl, 1 tbl, 186 ex

FIELD: biotechnologies.

SUBSTANCE: in a compound of formula ,

X means N or CH, R1 means hydrogen or cyano, R2 means saturated 4-7-membered residue of heterocyclyl, which is bound through a nitrogen atom that contains 1 to 2 heteroatoms chosen from N and O. Besides, heterocyclyl residue can be replaced with one substituent chosen from a group consisting of C3-C6-cycloalkyl, or with 1-4 fluorine atoms. The invention also refers to a method for obtaining compounds and to a medicine on their basis.

EFFECT: compounds can be used for production of a medicine suitable for being used in a method of treatment or prophylaxis of cardiovascular diseases, cardiac insufficiency, anemia, chronic diseases of kidneys and kidney failure.

16 cl, 1 tbl, 29 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and aims at the simultaneous control of coccidiosis and iron deficiency. The compound comprises triazinones of formulas (I) or (II) wherein R1 means CF3-SO2- or CF3-S-, R2 means CH3, each R4, R5 and R6 means Cl (chlorine) or pharmaceutically acceptable salts thereof, and iron compounds (3+) specified in a group consisting of: multinucleated complex iron (III) and polysaccharide compounds and ammonium-iron (III) citrate. What is also declared is using the above compounds for producing drug preparations.

EFFECT: using the declared group of inventions is effective for the simultaneous control of coccidiosis and iron deficiency; it is accompanied by no adverse phenomena; the compound ingredients have no negative effects on each other; and their biological activity preserves.

17 cl, 15 tbl, 7 ex

FIELD: biotechnologies.

SUBSTANCE: invention relates to production of peptide derivative mimetic of EPO, with the formula: R1-R2-(CH2)n1-R3-(CH2)n2-R4-R5 (I) and its pharmaceutical salts, where R1, R5 are selected from cyclic peptides with sequences SEQ ID NO:5, 6, 7 and 8; n1, n2 represent integer numbers independently selected from 0-10; R2, R4 are selected from -CO or -CH2; R3 is selected from O, S, CH2, N(CH2)n3NHR6, NCO(CH2)n4NHR6, CHOCONH(CH2)n5NHR6, CHSCON(CH2)n5NHR6 or CHNHCON(CH2)n5NHR6; where n3 represents an integer number selected from 1-10, n4 is an integer number selected from 2-10, n5 represents an integer number selected from 2-10, R6 is selected from H or derivatives of metoxyethylene glycol. The produced peptide or its pharmaceutically acceptable salt is used within a pharmaceutical composition for treatment of disorders characterised with EPO deficit, low or defective population of erythrocytes.

EFFECT: invention makes it possible to produce an agonist of EPO receptor having higher biological activity compared to existing EPO mimetics.

15 cl, 2 dwg, 5 tbl, 19 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, and namely to composition for prevention of iron deficiency anemia. Composition for prevention of iron deficiency anemia, which contains source of iron, source of copper, vitamins B1, B3, B6, B9, B12, ascorbic acid, extract from nettle leaves, extract from strawberry leaves, pantohematogen and auxiliary substances, with specified component ratio.

EFFECT: composition makes it possible to extend arsenal of methods for prevention of iron deficiency anemia and is effective.

4 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to iron-enriched food product, which contains iron source in form of solid particles, where particles include core, containing iron alginate, and external layer, which contains calcium alginate, where particles are obtained by method which includes the following stages: (i) formation of core, which contains iron alginate, by contact of bioavailable water-soluble salt of iron and one water-soluble alginate salt, (ii) contact of core with water solution of calcium salt, in concentration, which constitutes from 0.025 M to concentration of lower than solution saturation point, and (iii) separation of obtained solid product. Iron-enriched food product is applied for prevention and treatment of iron deficiency conditions of people.

EFFECT: solid particles are applicable for enrichment of food products with iron and is characterised by improved load ability, as well as possesses good stability under standard storage and application conditions.

11 cl, 9 dwg, 13 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology and pulmonology, and concerns treating the patients with chronic obstructive pulmonary disease and ischemic heart disease and cardiac failure complicated by anaemia. For this purpose, pre-treatment haemoglobin and serum iron are evaluated. In that case, if the hemoglobin level is less than 110 mm/l, and the serum iron level is less than 5.85 mmol/l, the conventional treatment involving ACE inhibitors, beta blockers, diuretics, antiaggregants, statins as well as salmeterol and berodual, is added by prescribing an anti-anaemic therapy with Epocrin and Ferrum Lek. Epocrin is administered in a dose of 50 IU/kg subcutaneously 6 times a week; Ferrum Lek is administered in a dose of Fe 100 mg in 5 ml intravenously twice a week. The therapeutic course is 3 months.

EFFECT: this dose schedule of the preparations provides reducing a length of treatment by improving the central haemodynamics, and enhancing the respiratory function.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns pharmaceutical preparations containing ferric chelate bisglycinate (2) associated with a mixture of sweetening agents with improved flavour.

EFFECT: invention refers to the use if said preparations in prevention and (or) treatment of pathological conditions caused by ferric deficiency.

12 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and nornalisation of alpha 2 antiplasmin activity in newborn calves with asiderotic anemia. Method includes administration of ferroglucinum -75 solution in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, once, and glicopin to drink in dose 6.0 mg/day for 6 days, starting simultaneously with ferroglucinum injection.

EFFECT: invention makes it possible to normalise level of 0,2 antiplasmin in newborn calves with asiderotic anemia, reduce risk of thrombotic complications, to make herd healthier, reduce murrain, increase weight gain, increase quality and volume of obtained meat and dairy products and in succeeding years obtain healthy offspring from said calves.

2 ex

FIELD: medicine.

SUBSTANCE: declared invention refers to veterinary science and aims at recovering the estrual cycling and fertility in cows suffering from hypo-ovarionism. The method involves single parenteral administration of the gonadotrophic preparation of a pregnant mare serum gonadotropin - folligon in a dose of 1,000 IU on the 7th day from the beginning of treatment with underlying pre-injections of 2.5% progesterone in a dose of 4 ml, on the 1st, 3rd and 5th days of the therapeutic course, 2% Sinestrol in a dose of 2 ml on the 1st and 3rd days, and Eleovit in a dose of 5 ml on the 1st and 7th day of treatment.

EFFECT: declared invention provides normalising the hormonal-metabolic status and the recovered functional ovarian activity in the cows.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: placenta hydrolyzate 1 ml mixed with lanolin 30 g before the procedure is applied on an anterior abdominal wall of a patient lying on his/her back in the projection of adhesions. That is followed by phonophoresis generated by UZT-1.07F ultrasonic therapeutic apparatus and sounded by an emitter of the diameter of 4 cm of the intensity of 0.4-0.6 W/cm2. The exposure mode is continuous; an emitter velocity is 1-1.5 cm/sec. The length of procedure is 5-7 minutes. The therapeutic course is 10 procedures.

EFFECT: reduced progression of abdominal adhesions and their manifestations by evident anti-inflammatory effect, reduced pain syndrome, higher adaptive body reserves.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: allogenic multipotent mesenchymal stromal cells in the number of 6 million cells/kg are introduced intravenously in a dose of 3.0 Gy into rats suffered from radiation exposure. Additionally, haemopoietic stem cells recovered from umbilical blood in the number of 300 thousand cells/kg are introduced. The cells are transplanted in such a manner 60 min after radiation exposure.

EFFECT: higher mitosis count that leads to a substantial cryptal epithelium increase.

3 tbl

FIELD: medicine.

SUBSTANCE: method involves intravenous allogeneic transplantation of multipotent mesenchymal stromal cells recovered from the placenta in an amount of 6 mln cells/kg. Additionally, haemopoietic stem cells recovered from umbilical blood in an amount of 300 thousand cells/kg are introduced.

EFFECT: method enables reducing the number of cytogenetically changed cells, promotes activating myeloid tissue regeneration in old laboratory animals.

4 tbl, 1 ex

FIELD: biotechnology.

SUBSTANCE: composition is proposed which comprises stem cells of human amniotic fluid with the phenotype CD73+/CD90+/CD105+/CK19+, nutrient medium, erythropoietin, epidermal growth factor, and collagen taken in an effective amount.

EFFECT: invention enables to increase the proliferative potential and viability of the cells, while simultaneously providing cytoprotective effect on the cells of the transplant and stimulation of migration and proliferation of patient's own cells, and also to reduce significantly the concentration of injectable cells and to activate vascularisation and regeneration at the defect site and can be used in therapy for elimination of congenital and acquired defects of soft tissue arising as the result of injuries, after removal of tumors, congenital diseases, age-related changes or other damages.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of veterinary and is intended for activation of reproductive function in Karakul sheep. A biological preparation, including a female placenta extract and vitamins, is characterised by the fact that it additionally contains phytoextracts (in which a physiological solution is used as an extractant) of seeds of desert forage plants - annual Salsola: Salsola sclerantha C.A.M, Gamanthus gamocarpus Mog, Climacoptera lanata Pall., and phytoextracts (in which the physiological solution is used as the extractant): of rhizomes of Sweet flag (Acorus calamus L.) and caper (Capparis spinosa L.) in a ratio placenta extract: phytoextracts as 1:2 and a water-soluble vitamin-amino acid complex "Chiktonic", with the following component ratio, ml: an extract of female placenta 100, a phytoextract of seeds of Salsola sclerantha C.A.M. 30, a phytoextract of seeds of GamanthusgamocarpusMog 40, a phytoextract of seeds of Climacoptera lanata Pall. 40, a phytoextract of rhizomes of Sweet flag (Acorus calamus L.) 40, a phytoextract of seeds of caper (Capparis spinosa L.) 50, the water-soluble vitamin-amino acid complex "Chiktonic" 2.

EFFECT: application of the claimed preparation contributes to activation and normalisation of reproductive function in sheep, increases synchronicity of passing ewes in the state of readiness and fertility.

3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, in particular to gastroenterology, and deal with treatment of ulcerative colitis and Crohn's disease. Method of treatment includes introduction into organism of therapeutically efficient quantity of attaching cells from placenta, cultivated in such a way as not to differentiate into adipocytes or osteocytes. Also claimed is application of said cells for obtaining medication, intended for treatment of ulcerative colitis or Crohn's disease. Claimed produced product for treatment of ulcerative colitis or Crohn's disease includes in packing form pharmaceutically efficient quantity of said cells.

EFFECT: inventions ensure essential reduction of inflammatory process in colon in modelling of said diseases, as well as due to pathological mechanisms of treatment in addition to T-lymphocyte suppression.

31 cl, 5 ex, 12 tbl, 16 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for producing a therapeutic biologically active preparation for treating dyspepsia in newborn calves. The method for producing a therapeutic biologically active preparation for treating dyspepsia in newborn calves consisting in the fact that the multiseptate gastric content and amniotic placental fluid are sampled from female foetus; the multiseptate gastric tissue is homogenised, combined with the amniotic placental fluid, settled, filtered, centrifuged; a produced liquid fraction is combined with the multiseptate gastric content in the certain environment.

EFFECT: preparation produced by the method described above possesses the improved therapeutic action in the newborn calves suffering dyspepsia.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pulmonology and physiotherapy, and may be used for treating acute pneumonias in debilitated patients living in industrial cities. That is ensured by 10 daily ultrasonic inhalations of 1% placenta hydrolysate at temperature 35°C for 10 minutes on an empty stomach or 40-60 minutes after meals. The inhalations are followed by the exposure to an ultra-high frequency electric field generated by automatically resonating UHF-80-3 Undaterm apparatus of output power up to 80 Wt, high-frequency oscillation frequency 27.12±0.6 MHz. The UHF exposure covers a patient sitting of a wooden chair. Condenser plates, each of the diameter 180 mm spaced 3 cm are placed on front and back surfaces of a chest above the inflammation centre from each side. An UHF dose is low-heat, has a power of 40-60 Wt; the procedure length is 10 minute; the therapeutic course makes 10 daily procedures. After 30 minutes, the UHF exposure is followed by medicine electrophoresis through 5% placenta hydrolysate applied on one of the temporary spacers. The exposure is generated by Potok-1 apparatus having current intensity 15-20 mA; the procedure length makes 20 minutes; the therapeutic course is 10 daily procedures with the patient lying on back on a bed. Two electrodes of the same size 10x15 cm are placed in a projection of the pathological centre, i.e. the first electrode is placed on the right or on the left on the back, and the second one - on the right or on the left at the front.

EFFECT: providing faster relief of the pathological process in the pulmonary tissue, prevented development of any complication and formation of the pulmonary chronic process, including due to the manifested secretolytic effect, the high effect of bronchial apparatus drainage, normalised immune status of the respiratory mucosa.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely a method for individual's addictive behaviour correction. The method for individual's addictive behaviour correction involving the simultaneous introduction into the individual's body a combination of organic preparations: Hirnstamm D5, Placenta D5, Hypophysis D5, Thymus D5, according to the specific schedule in a combination with the course of psychotherapy.

EFFECT: developing the method for individual's addictive behaviour correction.

3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel derivative of ferrocene 1-(1,1,1,3,3,3-hexafluoro-2-ferrocenylprop-2-yl)-imidazole of formula

which shows an antitumour activity. Also claimed is a method of its obtaining (versions).

EFFECT: invention makes it possible to obtain the novel derivative of ferrocene, which can be applied in medicine for chemotherapy of oncologic diseases.

4 cl, 1 dwg, 2 tbl, 3 ex

Up!